News | Lung Imaging | August 02, 2021

SIR considers image-guided thermal ablation to be an acceptable treatment option for patients with inoperable Stage I NSCLC, those with recurrent NSCLC, as well as patients with metastatic lung disease

SIR considers image-guided thermal ablation to be an acceptable treatment option for patients with inoperable Stage I NSCLC, those with recurrent NSCLC, as well as patients with metastatic lung disease

Getty Images


August 2, 2021 — The Society of Interventional Radiology (SIR) issued a new position statement on percutaneous lung ablation. The position statement was published in the August issue of the Journal of Vascular and Interventional Radiology (JVIR) with an accompanying quality improvement document, which establishes performance thresholds for patient safety.

“Minimally invasive, image-guided thermal ablation offers patients with early stage, non-small-cell lung cancer, recurring lung cancer, and metastatic disease a safe and effective treatment option,” said Mark Baerlocher, M.D., SIR’s standards division councilor and an author of the position statement and quality improvement document.

“The two publications provide physicians with guidance on everything from patient selection to treatment delivery and post-treatment care and follow-up, ensuring high-quality care that improves patients’ lives,” said Baerlocher, an interventional radiologist at the Royal Victoria Hospital, Ontario, Canada.

Lung cancer is the second most common newly diagnosed cancer in the United States, with an estimated 228,000 new cases diagnosed in 2020. It is also the leading cause of cancer-related death.

Interventional radiologists use image-guided thermal ablation to treat primary and secondary lung tumors. Based on the current evidence, the position statement recommends that radiofrequency ablation, cryoablation and microwave ablation are all appropriate forms of image-guided thermal ablation to treat these tumors. The method of ablation should be determined by lesion characteristics and risk mitigation, according to the new document.

“Evidence-based position statements are important means of improving patient outcomes,” said SIR President Mathew S. Johnson, M.D., FSIR, the Gary J. Becker Professor of Radiology Research at Indiana University School of Medicine in Indianapolis. “Future comparative studies on the use of thermal ablation to treat these forms of lung cancer will help improve the evidence base and allow us to make stronger recommendations to the benefit of patients.”

The position statement was developed by a multidisciplinary group of authors including interventional radiology, medical oncology, thoracic surgery and radiation oncology specialists. It is endorsed by the Canadian Association for Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe and the Society of Interventional Oncology.

Read the full position statement and quality improvement document on jvir.org.

Related Content

News | Proton Therapy

July 1, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology ...

Time July 01, 2022
arrow
News | Prostate Cancer

July 1, 2022 — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care ...

Time July 01, 2022
arrow
News | Magnetic Resonance Imaging (MRI)

June 30, 2022 — When a patient with head and neck cancer has surgery to remove it, they often need reconstructive ...

Time June 30, 2022
arrow
News | Proton Therapy

June 29, 2022 — ProtOnART builds upon the partners’ long-standing research efforts and shared ambition that an online ...

Time June 29, 2022
arrow
News | Lung Imaging

June 29, 2022 — Building on Penn Medicine’s years of research and use of imaging technology that illuminates tumor ...

Time June 29, 2022
arrow
News | Proton Therapy

June 27, 2022 — Varian, a Siemens Healthineers company, announced that the U.S. Food and Drug Administration (FDA) ...

Time June 28, 2022
arrow
News | Coronavirus (COVID-19)

June 27, 2022 — Three articles and an accompanying editorial provide information on the effects of Long COVID in the ...

Time June 28, 2022
arrow
News | Radiation Oncology

June 27, 2022 — Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they ...

Time June 28, 2022
arrow
News | Radiation Therapy

June 24, 2022 — Recently, a collaborated research team led by Prof. LI Hai and Hongzhi Wang from Hefei Institutes of ...

Time June 24, 2022
arrow
News | Contrast Media

June 23, 2022 — Supply chain disruptions have created critical shortages of Omnipaque (iohexol) and Visipaque (iodixanol ...

Time June 23, 2022
arrow
Subscribe Now